Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
Part II: Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia

The Investigators propose to test the hypothesis that GCSF enhances the clinical outcome of biliary atresia in a multi-institutional Phase 2 trial to prospectively evaluate the safety and efficacy of GCSF in each of the 2 groups of newly diagnosed BA patients: KBA (i.e., Kasai-operated) or NoK (i.e., patients who …

conjugated bilirubin
direct bilirubin
cholangiography
cholestasis
filgrastim
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

This study is to evaluate the efficacy of tucidinostat combined with exemestane as neoadjuvant strategy in estrogen receptor-positive early breast cancer patients and explore the genetic model which can predict neoadjuvant endocrine therapeutic results.

invasive breast cancer
exemestane
metastasis
tucidinostat
breast cancer
  • 2 views
  • 05 Aug, 2020
Histopathologic Effect of Calcium Electroporation on Cancer in the Skin

In this phase II study we investigate the effect of calcium electroporation on cancer in the skin investigated by histopathology.

cancer
endocrine therapy
metastasis
hormone therapy
calcium
  • 0 views
  • 16 Feb, 2024
  • 1 location
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Background People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs …

giant cell tumors
carcinoid
neuroendocrine tumor
carcinosarcoma
carcinoma lung
  • 0 views
  • 16 Feb, 2024
  • 1 location
bpMRI and Risk Based Shared Clinical Decision Making in Prostate Cancer Diagnosis

The shortcoming of the pre-biopsy prostate MRI approach is the recommendation to biopsy all men post-MRI even if there is no lesion seen in MRI, ie. risk of PCa is very low.

biopsy of prostate
digital rectal examination
cancer diagnosis
  • 0 views
  • 16 Feb, 2024
  • 4 locations
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients

This is an open-label, non-randomised, phase II, exploratory, multi-country and multi-centre clinical trial. Chemotherapy-nave patients with EML4-ALK rearrangement and with locally advanced or metastatic non-small cell lung cancer patients will be selected. Patients enrolled in the study will receive brigatinib 90mg for the first 7 days (D 1-7 at cycle …

heart failure
metastasis
hepatitis b
chemo-radiotherapy
brigatinib
  • 0 views
  • 16 Feb, 2024
  • 15 locations
AIM1: Adequate Selection of Patients for Thyroid Biopsy: Evaluation of a Shared Decision Making Conversation Aid

There is an epidemic of thyroid cancer that is harmful to patients and the medical system. The study hypothesizes that the use of an electronic conversation aid during clinical visits can help patients and clinicians collaborate when deciding the next step in management for a thyroid nodule. The study aims …

thyroid biopsy
cancer
aim1
thyroid nodule
  • 0 views
  • 05 Aug, 2020
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial

PEGASUS is a prospective multi-centric study designed to prove the feasibility of using liquid biopsy to guide the post-surgical and post-adjuvant clinical management in 140 microsatellite stable Stage-III and T4N0 Stage-II colon cancer patients.

folfiri regimen
colon cancer
cancer
adjuvant
stage ii colon cancer
  • 0 views
  • 16 Feb, 2024
  • 9 locations
HDR Brachytherapy 68-Ga-RM2 PET 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer

This study is being conducted to determine whether the combination of imaging agents 68-Ga RM2 and 68-Ga PMSA11 is better at assessing response to high dose rate (HDR) local therapy than standard imaging or biopsy in patients with known prostate cancer (PC)

brachytherapy
pet/mri
local therapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
Radiomics Tool for Pulmonary Nodule Risk Stratification

The primary outcome variable is appropriate pulmonary nodule management at the index clinic visit, defined as the composite proportion of benign pulmonary nodules managed with surveillance and malignant pulmonary nodules managed with biopsy or empiric treatment. Final pulmonary nodule diagnosis will be categorized as malignant or benign. If the pathology …

  • 0 views
  • 11 Jul, 2024
  • 1 location